MaRS Innovation partners on Triphase oncology development accelerator.

MaRS Innovation, a Canada-based commercialisation firm working with several universities in the Toronto area, has partnered with the Fight Against Cancer Innovation Trust (FACIT) to turn the Triphase Accelerator Corporation into an oncology development accelerator.

Triphase, an Ontario Institute for Cancer Research, was originally formed in 2010 by MaRS and FACIT to be a cancer-focused biotech development firm which aimed to reduce time and expense between new drug applications and the proof-of-concept phase.

Following its formation, Triphase entered into an…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?